RT Journal Article
SR Electronic
T1 Chest wall abnormalities in Swiss childhood cancer survivors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.24.21250393
DO 10.1101/2021.01.24.21250393
A1 Kasteler, Rahel
A1 Lichtensteiger, Christa
A1 Schindera, Christina
A1 Ansari, Marc
A1 Kuehni, Claudia E.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.24.21250393.abstract
AB Background Chest wall abnormalities are a poorly studied complication after treatment for childhood cancer. Chest wall abnormalities are not well described in the literature, and little is known on the impact on daily life of survivors.Methods We investigated chest wall abnormalities in the nationwide, population-based cohort study (Swiss Childhood Cancer Survivor Study) with a questionnaire survey to describe prevalence and risk factors. We then interviewed a nested sample of survivors to understand types of chest wall abnormalities and their impact on daily life of survivors.Results 48 of 2,382 (95%CI 2%–3%) survivors reported a chest wall abnormality. Risk factors were older age at cancer diagnosis (16–20 years; OR 2.5, 95%CI 1.0– 6.1), lymphoma (OR 3.8, 95%CI 1.2–11.4), and central nervous system tumors (OR 9.5, 95%CI 3.0–30.1) as underlying disease, and treatment with thoracic radiotherapy (OR 2.0, 95%CI 1.0–4.2), surgery to the chest (OR 4.5, 95%CI 1.8–11.5), or chemotherapy (OR 2.9, 95%CI 1.0–8.1) .The nature of the chest wall abnormalities varied and included thoracic wall deformities (30%), deformations of the spine (5%) or both (55%), and scars (10%). Chest wall abnormalities affected the daily life in two thirds (13/20) of those who reported these problems, and 15 (75%) had required chest wall abnormalities-related medical attention.Conclusion It is important that during follow-up care physicians pay attention to chest wall abnormalities, which are rare late-effect of cancer treatment, but can considerably affect well-being of cancer survivors.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03297034Funding StatementThis study was supported by the Swiss Cancer League (KFS-4157-02-2017 and KLS-3886-02-2016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Bern approved the SCCR and the SCCSS (KEK-BE: 166/2014), and the Swiss Childhood Cancer Survivor Study is registered at ClinicalTrials.gov (identifier: NCT03297034).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly available due to the local data safety agreement but are available from the corresponding author on reasonable request.CIConfidence intervalCNSCentral nervous systemIQRInterquartile rangeNNumberOROdds ratioPP-valueSCCRSwiss Childhood Cancer RegistrySCCSSSwiss Childhood Cancer Survivor Study